Clal Biotechnology Industries (CBI) News
12 articles
כלל ביו: אליסיו פרסמה תשקיף להנפקה בארה"ב
Elicio, a biotechnology company, has announced plans to go public on the NASDAQ. The company, which is backed by the industry conglomerate Kalyon Industries, is expected to raise $40-50 million through the IPO. Elicio specializes in immunotherapy and develops Amphiphile Vaccines, a technology that stimulates an effective immune response against cancer cells. Their leading product, ELI-002, a targeted therapeutic vaccine against RAS protein-mutated cancers, is currently in Phase 1/2 clinical trials. The IPO details, including the stock price and the number of shares offered, may change during the road show.
Public Trading
Clal Biotech and partners file to raise $100m Nasdaq SPAC
Clal Biotechnology Industries Ltd. has filed confidentially for a special purpose acquisition company (SPAC) called Cactus Acquisition Corp. to raise $100 million in an IPO on Nasdaq. Cactus will seek an Israeli life sciences company to acquire or merge with. The partnership between Clal Biotech, Vincent Tchenguiz, and Israel Biotech Fund (IBF) will hold a 33.33% stake in Cactus, and the three partners will receive an overall 20% stake in the merged company. The chairman of Cactus will be Homi Shamir, and the CEO of Clal Biotech, Ofer Gonen, will serve as CEO of Cactus. The target company of the merger is expected to have a valuation of several hundred million dollars.
AcquisitionPublic TradingManagement Changes
Clal Biotech to form $100m SPAC
Clal Biotechnology Industries is forming a SPAC and spinning off its medical technology funds. The company also declared a dividend and announced a share buyback program. The plan for the SPAC is to raise $100 million to invest in a company valued between $500 million and $1 billion. The company is looking for a pharmaceutical or digital health company connected to pharmaceuticals. Clal Biotech is also selling its Anatomy fund portfolio to Almeda Ventures. The partners in the Anatomy funds will receive participation units in Almeda Ventures.
Public TradingPartners
Clal Biotech jumps as portfolio co joins Covid-19 vaccine race
Elicio Therapeutics, a portfolio company of Clal Biotechnology Industries Ltd., reported positive results in pre-clinical studies of its COVID-19 vaccine candidate. The company plans to begin human clinical trials in the fourth quarter of 2020. As a result, Clal Biotechnology Industries saw a 23% increase in its share price on the Tel Aviv Stock Exchange, reaching a market cap of NIS 199 million. Elicio Therapeutics combines materials science and immunology to develop immunotherapies for aggressive cancers. The company has raised $75 million to date for its cancer vaccination research.
InvestmentPublic Trading
Yelin Lapidot to invest NIS 20m in Clal Biotech
Yelin Lapidot has decided to buy an 8% stake in Clal Biotechnology at the market price, amounting to a NIS 20 million investment. The investment will give Yelin Lapidot an 8% stake, and may persuade other concerns to invest in Clal Biotech. The Clal Biotechnology share rose 4% on the news, pushing the funds market cap up to NIS 491 million.
Investment
Clal Biotech co Luk buys Ataxion Therapeutics
Clal Biotechnology Industries Ltd. has announced the permanent appointment of Ofer Gonen as CEO. The company also announced the acquisition of Ataxion Therapeutics by Luc Therapeutics, a portfolio company of Clal Biotechnology. The deal will result in Clal Biotechnology owning a 20-24% stake in Luc Therapeutics. The companys market cap has increased by 21% this year, reaching NIS 408 million. The acquisition is part of Clal Biotechnologys strategy to expand its presence in the brain science sector. Atlas Venture, Novartis, and Siniona are among the investors involved in the deal. The article does not mention any specific customers or the valuation or investment amounts. The event described in the article occurred on March 7, 2017.
AcquisitionInvestment
Clal Biotech appoints Julian Adams president
Israeli life sciences investment company Clal Biotechnology Industries Ltd. has appointed Dr. Julian Adams as president and chief science officer. Dr. Adams has over 30 years of experience in drug discovery and development, with a focus on oncology. He has previously held senior positions at Infinity Pharmaceuticals and Millennium Pharmaceuticals, where he led the Velcade program. Clal Biotechnology Industries expects that Dr. Adams expertise will enhance and expand their operational and strategic capabilities.
Management Changes
Andromeda trial failure spells likely end of company
Clal Biotechnologys share price fell 20% following the publication of the failed clinical trial results for their drug DiaPep277, developed for the treatment of juvenile diabetes. The companys former parent company, Andromeda, had an option to buy back Clal Biotechnology, but it is unlikely to exercise it due to the negative trial results. Clal Biotechnologys image has suffered as a result of the failed trial, and the future of the drug and the companys employees is uncertain. Hyperion, the company that acquired Andromeda, has been sold to Horizon Pharma. Clal Biotechnology will assess the trial data and decide whether further investment is justified.
Investment
Clal Biotech unit signs Novartis deal
Mnemosyne, a company in which Clal Biotechnology Industries Ltd. owns a stake, has signed an agreement with Novartis for the commercialization of its drug for psychiatric and neurological disorders. Novartis will take over the drug development process and pay Mnemosyne $6 million upfront, $380 million in royalties if the product passes milestones, and 10% royalties on revenue. This agreement is unusual for a product in the preclinical development stage. Mnemosyne is one of three companies acquired by Clal Biotechnology in a deal with Len Blavatnik. The payment terms for the deal were favorable for Clal Biotechnology. Mnemosyne will likely become a significant holding for Clal Biotechnology. Clal Biotechnology had a significant loss in 2014, but payments from this agreement could be recognized as profit.
Partners
Clal Biotech Sells Pidilizumab Cancer Treatment Rights to Medivation
Clal Biotechnology Industries has sold the exclusive worldwide commercialization rights for its cancer treatment pidilizumab to Medivation. This is good news for Clal as it is currently embroiled in a scandal. Under the license agreement, Medivation will be responsible for all development, regulatory, and commercialization activities for pidilizumab. The arrangement also includes a manufacturing and supply agreement. Medivation is a biopharmaceutical company focused on the rapid development of novel therapies.
Partners
Clal Biotech to pay $7.5m for Blavatnik cos - in 12 years
Clal Biotechnology Industries Ltd. has approved the acquisition of three life sciences holdings from its controlling shareholder, Len Blavatniks Access Industries Inc. The company will also acquire Teva Pharmaceutical Industries Ltd.s holdings in oncology company CureTech. These measures are part of Clal Biotechs strategic change from a holding company to an independent pharmaceutical company. The acquisitions will give Clal Biotech a base of operations in the US and expand its portfolio. The closure of the deal is subject to approval by Clal Biotechs general shareholders meeting. The payment for CureTech will be based on future revenue, up to a maximum of $44.5 million. Clal Biotech believes that CureTechs actual value is much higher than the estimated value of $15 million.
Acquisition
Clal Biotech buys Biomedical Investments
Clal Biotechnology Industries Ltd. has announced its acquisition of Biomedical Investments (1997) Ltd. for NIS 84 million in cash, shares, and warrants. The acquisition is a growth-positive move for Clal Biotech. Biomedical Investments was jointly founded by Teva Pharmaceutical Industries Ltd., the Arison family, and Len Abramson. Both Clal Biotech and Biomedical Investments are managed by Arte Venture Group, and Teva has a minority interest in both companies. Biomedical Investments has raised $20 million to date and has returned $15 million from exits by portfolio companies. The most important holding of Biomedical Investments is a 20% stake in stem cell therapies developer Gamida Cell, which is currently undergoing a Phase III clinical trial. Clal Biotechs share price rose 4.4% following the announcement of the acquisition.
Acquisition
